{
    "data": [
        {
            "id": "DJN_DN20260226013064:0",
            "title": "RenaissanceRe Is Maintained at Hold by TD Cowen",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:32 GMT) </span></strong><span>RenaissanceRe Price Target Raised to $290.00/Share From $280.00 by TD Cowen</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226013064:0/",
            "pub_date": "2026-02-27 02:32:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226013066:0",
            "title": "Chime Financial Is Maintained at Neutral by UBS",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226013066:0/",
            "pub_date": "2026-02-27 02:32:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_RSZ6109Ua:0",
            "title": "REG - Dialight PLC Schroders PLC - Holding(s) in Company",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 6109U  Dialight PLC  26 February 2026   </span><p class=\"\"><span>TR-1: Standard form for notification of major holdings</span></p><p class=\"\"><span>1. Issuer Details</span></p><p class=\"\"><span>ISIN</span></p><p class=\"\"><span>GB0033057794</span></p><p class=\"\"><span>Issuer Name</span></p><p class=\"\"><span>DIALIGHT PLC</span></p><p class=\"\"><span>UK or Non-UK Issuer</span></p><p class=\"\"><span>UK</span></p><p class=\"\"><span>2. Reason for Notification</span></p><p class=\"\"><span>An acquisition or disposal of voting rights</span></p><p class=\"\"><span>3. Details of person subject to the notification obligation</span></p><p class=\"\"><span>Name</span></p><p class=\"\"><span>Schroders Plc</span></p><p class=\"\"><span>City of registered office (if applicable)</span></p><p class=\"\"><span>London Wall, Barbican</span></p><p class=\"\"><span>Country of registered office (if applicable)</span></p><p class=\"\"><span>England</span></p><p class=\"\"><span>4. Details of the shareholder</span></p><p class=\"\"><span>Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above</span></p><p class=\"\"><span>City of registered office (if applicable)</span></p><p class=\"\"><span>Country of registered office (if applicable)</span></p><p class=\"\"><span>5. Date on which the threshold was crossed or reached</span></p><p class=\"\"><span>08-Jan-2026</span></p><p class=\"\"><span>6. Date on which Issuer notified</span></p><p class=\"\"><span>09-Jan-2026</span></p><p class=\"\"><span>7. Total positions of person(s) subject to the notification obligation</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td></td><td><p class=\"\"><span>% of voting rights attached to shares (total of 8.A)</span></p></td><td><p class=\"\"><span>% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)</span></p></td><td><p class=\"\"><span>Total of both in % (8.A + 8.B)</span></p></td><td><p class=\"\"><span>Total number of voting rights held in issuer</span></p></td></tr><tr><td><p class=\"\"><span>Resulting situation on the date on which threshold was crossed or reached</span></p></td><td><p class=\"\"><span>13.986892</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>13.986892</span></p></td><td><p class=\"\"><span>5623494</span></p></td></tr><tr><td><p class=\"\"><span>Position of previous notification (if applicable)</span></p></td><td><p class=\"\"><span>14.372708</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>14.372708</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>8. Notified details of the resulting situation on the date on which the threshold was crossed or reached</span></p><p class=\"\"><span>8A. Voting rights attached to shares</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Class/Type of shares ISIN code(if possible)</span></p></td><td><p class=\"\"><span>Number of direct voting rights (DTR5.1)</span></p></td><td><p class=\"\"><span>Number of indirect voting rights (DTR5.2.1)</span></p></td><td><p class=\"\"><span>% of direct voting rights (DTR5.1)</span></p></td><td><p class=\"\"><span>% of indirect voting rights (DTR5.2.1)</span></p></td></tr><tr><td><p class=\"\"><span>GB0033057794</span></p></td><td></td><td><p class=\"\"><span>5623494</span></p></td><td></td><td><p class=\"\"><span>13.986892</span></p></td></tr><tr><td><p class=\"\"><span>Sub Total 8.A</span></p></td><td colspan=\"2\"><p class=\"\"><span>5623494</span></p></td><td colspan=\"2\"><p class=\"\"><span>13.986892%</span></p></td></tr></tbody></table></div><p class=\"\"><span>8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Type of financial instrument</span></p></td><td><p class=\"\"><span>Sub Total 8.B1</span></p></td></tr><tr><td><p class=\"\"><span>Expiration date</span></p></td><td colspan=\"2\"></td></tr><tr><td><p class=\"\"><span>Exercise/conversion period</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Number of voting rights that may be acquired if the instrument is exercised/converted</span></p></td><td></td></tr><tr><td><p class=\"\"><span>% of voting rights</span></p></td></tr></tbody></table></div><p class=\"\"><span>8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Type of financial instrument</span></p></td><td><p class=\"\"><span>Sub Total 8.B2</span></p></td></tr><tr><td><p class=\"\"><span>Expiration date</span></p></td><td colspan=\"3\"></td></tr><tr><td><p class=\"\"><span>Exercise/conversion period</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Physical or cash settlement</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Number of voting rights</span></p></td></tr><tr><td><p class=\"\"><span>% of voting rights</span></p></td></tr></tbody></table></div><p class=\"\"><span>9. Information in relation to the person subject to the notification obligation</span></p><p class=\"\"><span>2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Ultimate controlling person</span></p></td><td><p class=\"\"><span>Name of controlled undertaking</span></p></td><td><p class=\"\"><span>% of voting rights if it equals or is higher than the notifiable threshold</span></p></td><td><p class=\"\"><span>% of voting rights through financial instruments if it equals or is higher than the notifiable threshold</span></p></td><td><p class=\"\"><span>Total of both if it equals or is higher than the notifiable threshold</span></p></td></tr><tr><td><p class=\"\"><span>Schroders plc</span></p></td><td></td><td></td><td></td><td></td></tr><tr><td><p class=\"\"><span>Schroders plc</span></p></td><td><p class=\"\"><span>Schroder Administration Limited</span></p></td><td></td><td></td><td></td></tr><tr><td><p class=\"\"><span>Schroders plc</span></p></td><td><p class=\"\"><span>Schroder International Holdings Limited</span></p></td><td></td><td></td><td></td></tr><tr><td><p class=\"\"><span>Schroders plc</span></p></td><td><p class=\"\"><span>Schroder Investment Management Limited</span></p></td><td><p class=\"\"><span>13.986892</span></p></td><td></td><td><p class=\"\"><span>13.986892%</span></p></td></tr></tbody></table></div><p class=\"\"><span>10. In case of proxy voting</span></p><p class=\"\"><span>Name of the proxy holder</span></p><p class=\"\"><span>The number and % of voting rights held</span></p><p class=\"\"><span>The date until which the voting rights will be held</span></p><p class=\"\"><span>11. Additional Information</span></p><p class=\"\"><span>None</span></p><p class=\"\"><span>12. Date of Completion</span></p><p class=\"\"><span>09-Jan-2026</span></p><p class=\"\"><span>13. Place Of Completion</span></p><p class=\"\"><span>London</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  HOLSESFAMEMSEDE</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_RSZ6109Ua:0-reg-dialight-plc-schroders-plc-holding-s-in-company/",
            "pub_date": "2026-02-27 02:32:16",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L6N3ZM168:0",
            "title": "Soybeans ease on profit taking after hitting 20-month peak on demand hopes",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><div class=\"summary-diQOvrPB\"><div class=\"summaryTitle-diQOvrPB\">Key points:</div><span><ul class=\"list-bmN0_SHH\"><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Biofuel demand supports soybean, soyoil futures</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Corn futures decline due to profit-taking and low export sales</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Wheat futures rise after three sessions of losses</span></li></ul></span></div><span><p class=\"\"><span>By Karl Plume</span></p><p class=\"\"><span>    U.S. soybean futures rallied on Thursday to their highest since mid-2024 on hopes for more U.S. biofuel demand and Chinese imports before the market eased in a profit-taking retreat.</span></p><p class=\"\"><span>Corn futures also declined on profit-taking and technical selling, and as weekly corn export sales fell below trade expectations, while wheat firmed following three sessions of losses.</span></p><p class=\"\"><span>Chicago Board of Trade May soybeans (SK26) were down 8-1/2 cents at $11.56-1/4 a bushel by 12:15 a.m. CST (1815 GMT) after the most-active contract </span><span> rose to the highest point in 20 months. Soyoil futures (BOv1) rose for a fourth straight day and hit the highest level since mid-September 2023.</span></p><p class=\"\"><span>Both markets gained on news on Wednesday that the U.S. Environmental Protection Agency would send its proposal for new biofuel blending mandates to the White House, with an expected rule to be finalised by the end of March. The move brings the market closer to ending recent uncertainty over demand for biofuels and feedstocks like soy.</span></p><p class=\"\"><span>A Reuters report on Thursday that the U.S. government plans to reallocate at least 50% of exempted biofuel blending obligations to big refiners, known as small refinery exemptions, or SREs, lent further support.</span></p><p class=\"\"><span>\"If we have a reallocation of 50% of SREs, that is important and would mean that there's going to be greater biofuel demand,\" said Dan Basse, president of AgResource Co.</span></p><p class=\"\"><span>Questions about soybean demand from top importer China amid tariff uncertainty and ahead of U.S. President Donald Trump's trip to the country this spring kept the market on edge.</span></p><p class=\"\"><span>CBOT May wheat (WK26) was up 3-3/4 cents at $5.73-1/2 a bushel after retreating from a three-month peak at the start of the week. May corn (CK26) was down 1-1/4 cents at $4.40-3/4 a bushel, dipping from a 1-1/2-month high after weekly U.S. data showed a drop in export sales to the lowest in seven weeks.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L6N3ZM168:0-soybeans-ease-on-profit-taking-after-hitting-20-month-peak-on-demand-hopes/",
            "pub_date": "2026-02-27 02:32:24",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_FWN3ZM23Q:0",
            "title": "Cannabis Teamsters At Cresco Labs Go On Strike",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Teamsters:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>TEAMSTERS: CANNABIS TEAMSTERS AT CRESCO LABS GO ON STRIKE - WEBSITE</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZM23Q:0-cannabis-teamsters-at-cresco-labs-go-on-strike/",
            "pub_date": "2026-02-27 02:32:41",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938714:0",
            "title": "TRUP: 2026 guidance highlights pricing-led growth, margin expansion, and broader customer acquisition",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Revenue growth in 2026 will be pricing-led, with increased headcount contribution and margin expansion. Customer acquisition is broadening through vets, breeders, and early pet parent engagement, while technology and new products drive efficiency and address affordability.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938714:0-trup-2026-guidance-highlights-pricing-led-growth-margin-expansion-and-broader-customer-acquisition/",
            "pub_date": "2026-02-27 02:32:52",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938715:0",
            "title": "CG: Record 2025 results and ambitious 2028 targets driven by diversified, tech-enabled growth",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>The firm delivered record financial results in 2025, set ambitious 2028 targets, and is leveraging diversification, technology, and a client-centric approach to drive organic growth. AI and data are embedded across operations, while high-conviction sectors and a robust balance sheet support future expansion.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938715:0-cg-record-2025-results-and-ambitious-2028-targets-driven-by-diversified-tech-enabled-growth/",
            "pub_date": "2026-02-27 02:32:57",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226013080:0",
            "title": "LifeStance Health Group Is Maintained at Buy by UBS",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:33 GMT) </span></strong><span>LifeStance Health Group Price Target Raised to $12.00/Share From $10.00 by UBS</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226013080:0/",
            "pub_date": "2026-02-27 02:33:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_RSZ6104Ua:0",
            "title": "REG - Legal&Gen UCITS ETF - Result of EGM",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><span>RNS Number : 6104U  Legal &amp; General UCITS ETF PLC  26 February 2026   </span><p class=\"\"><span>26 February 2026</span></p><p class=\"\"><span>LEGAL &amp; GENERAL UCITS ETF PLC</span></p><p class=\"\"><span>(an open-ended investment company with variable capital structured as an umbrella fund with segregated liability between its sub-funds)</span></p><p class=\"\"><span>RESULT OF THE EXTRAORDINARY GENERAL MEETING</span></p><p class=\"\"><span>Legal &amp; General UCITS ETF Plc (the \"Company\") wishes to announce that the extraordinary general meeting (the \"EGM\") of the L&amp;G Emerging Markets ESG Exclusions Paris Aligned UCITS ETF, was held at the registered office of the Company at 70 Sir John Rogerson's Quay, Dublin 2, Ireland, on 26 February at 3:00 p.m. All resolutions proposed in the Notice of EGM were passed as follows:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><span>RESOLUTIONS</span></td><td><p class=\"\"><span>Ordinary Resolution</span></p><p class=\"\"><span>That the investment objective of L&amp;G Emerging Markets ESG Exclusions Paris Aligned UCITS ETF (to be renamed L&amp;G Emerging Markets Equity UCITS ETF) is hereby changed to reads as follows \"The investment objective of the Fund is to provide exposure to the large and mid-cap equity market in emerging markets\".</span></p></td></tr><tr><td><span>FOR</span></td><td><p class=\"\"><span>4,676,956</span></p></td></tr><tr><td><span>AGAINST</span></td><td><p class=\"\"><span>-</span></p></td></tr><tr><td><span>ABSTAIN</span></td><td><p class=\"\"><span>-</span></p></td></tr></tbody></table></div><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Number of shares of the Company in respect of which proxy appointments had been validly made:</span></p></td><td><p class=\"\"><span>4,676,956</span></p></td></tr><tr><td><p class=\"\"><span>Number of shares of the Company in respect of which the vote was directed to be withheld:</span></p></td><td><p class=\"\"><span>-</span></p></td></tr></tbody></table></div><p class=\"\"><span>Accordingly, the proposed resolutions were approved by the Shareholders in attendance or represented at the EGM.</span></p><p class=\"\"><span>The changes set out in the circular dated 4 February 2026 are expected to take effect on or around 27 February 2026 (the \"Effective Date\").</span></p><p class=\"\"><span>Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the circular dated 4 February 2026 which is available on National Storage Mechanism (NSM) https://data.fca.org.uk/#/nsm/nationalstoragemechanism.</span></p><p class=\"\"><span>FURTHER INFORMATION</span></p><p class=\"\"><span>Legal &amp; General Investment Management Limited</span></p><p class=\"\"><span>Tel: 0345 070 8684</span></p><p class=\"\"><span>Email: fundsales@lgim.com</span></p><p class=\"\"><span>J&amp;E Davy (Listing Sponsor)</span></p><p class=\"\"><span>Enquiries: Brian Garrahy                                             </span></p><p class=\"\"><span>Tel: +353 1 6796363</span></p><p class=\"\"><span>Email:  DCF@Davy.ie</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  ROMAKABBFBKDPBB</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_RSZ6104Ua:0-reg-legal-gen-ucits-etf-result-of-egm/",
            "pub_date": "2026-02-27 02:33:23",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_FWN3ZM2BC:0",
            "title": "Google Introduces New AI-Powered Features In Google Translate",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Google:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>GOOGLE: INTRODUCING NEW AI-POWERED FEATURES IN GOOGLE TRANSLATE - BLOG</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>GOOGLE: AI-POWERED UPDATES IN GOOGLE TRANSLATE AVAILABLE IN U.S. AND INDIA ON TRANSLATE APP, COMING SOON TO WEB</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZM2BC:0-google-introduces-new-ai-powered-features-in-google-translate/",
            "pub_date": "2026-02-27 02:33:30",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_FWN3ZM28N:0",
            "title": "Apple Says iPhone & iPad Approved To Handle Classified NATO Information",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Apple Inc </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>APPLE INC: IPHONE AND IPAD APPROVED TO HANDLE CLASSIFIED NATO INFORMATION</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>APPLE INC: IPHONE AND IPAD RUNNING IOS 26 AND IPADOS 26 ARE CERTIFIED FOR CLASSIFIED INFORMATION USE IN ALL NATO NATIONS - WEBSITE</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZM28N:0-apple-says-iphone-ipad-approved-to-handle-classified-nato-information/",
            "pub_date": "2026-02-27 02:34:03",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938722:0",
            "title": "PALI: Novel PDE4 inhibitor shows promise in UC and Crohn’s, with phase 2 trials and funding secured",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>A strategic pivot in 2023 led to the acquisition and advancement of a novel, once-daily PDE4 inhibitor with improved tolerability for UC and Crohn’s. Early clinical data show promising efficacy and safety, with phase 2 UC trials set for 2024 and strong financial runway into 2029.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938722:0-pali-novel-pde4-inhibitor-shows-promise-in-uc-and-crohn-s-with-phase-2-trials-and-funding-secured/",
            "pub_date": "2026-02-27 02:35:15",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938724:0",
            "title": "Z: Strong growth, AI-driven innovation, and integrated services position the business for long-term margin expansion",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Revenue and EBITDA grew strongly in 2025, with continued margin expansion and disciplined cost management. Strategic focus remains on integrating services, leveraging AI for productivity, and expanding both the rentals and mortgage businesses. Long-term targets include significant margin growth and leadership in the housing ecosystem.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938724:0-z-strong-growth-ai-driven-innovation-and-integrated-services-position-the-business-for-long-term-margin-expansion/",
            "pub_date": "2026-02-27 02:35:18",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938696:0",
            "title": "SLR: EBITDA beat, 3 GW capacity, long-term PPAs, and rapid data center and battery growth",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Surpassed EBITDA guidance with €266M, expanded to 3 GW capacity, and secured long-term PPAs, including a 40-year solar and 10-year hybrid battery deal. Rapid growth in data center and battery segments, with strong cash flow and European expansion underway.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938696:0-slr-ebitda-beat-3-gw-capacity-long-term-ppas-and-rapid-data-center-and-battery-growth/",
            "pub_date": "2026-02-27 02:27:27",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938698:0",
            "title": "IONS: Priority review for olezarsen accelerates launch plans amid robust pipeline and commercial momentum",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>FDA granted priority review for olezarsen in sHTG, enabling a potential mid-year launch. Multiple late-stage pipeline assets are set for approvals and launches through 2027, with a focus on high-risk sHTG patients and continued expansion in neurology. Financial guidance will be updated to reflect accelerated timelines.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938698:0-ions-priority-review-for-olezarsen-accelerates-launch-plans-amid-robust-pipeline-and-commercial-momentum/",
            "pub_date": "2026-02-27 02:27:28",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938697:0",
            "title": "AQST: Anaphylm sublingual film targets FDA approval in Q1 2027, aiming to disrupt the allergy market",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>The company is advancing a sublingual epinephrine film, Anaphylm, targeting the growing severe allergy market and aiming to replace auto-injectors with a more convenient alternative. Regulatory resubmission is planned for Q3, with potential approval in Q1 2027, supported by a strong cash position and a ready commercial team.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938697:0-aqst-anaphylm-sublingual-film-targets-fda-approval-in-q1-2027-aiming-to-disrupt-the-allergy-market/",
            "pub_date": "2026-02-27 02:27:28",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938699:0",
            "title": "CCAP: Q4 net investment income covered the dividend, but NAV declined amid portfolio unrealized losses",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 2025 net investment income was $0.45 per share, covering the dividend, with NAV per share declining to $19.10 due to unrealized losses. Portfolio remains diversified and first lien-focused, while management reviews dividend and fee structures amid a competitive private credit market.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938699:0-ccap-q4-net-investment-income-covered-the-dividend-but-nav-declined-amid-portfolio-unrealized-losses/",
            "pub_date": "2026-02-27 02:27:30",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_RSZ6102Ua:0",
            "title": "REG - Intl Con Airline Grp - Final dividend and return of excess cash",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 6102U  International Cons Airlines Group  26 February 2026   </span><p class=\"\"><span>INTERNATIONAL CONSOLIDATED AIRLINES GROUP, S.A.</span></p><p class=\"\"><span>(\"IAG\" or the \"Company\")</span></p><p class=\"\"><span>Final dividend and return of excess cash</span></p><p class=\"\"><span>IAG today announces its decision to recommend to shareholders a final dividend of €0.05 per share in respect of the financial year to 31 December 2025.</span></p><p class=\"\"><span>Together with the interim dividend of €0.048 paid in December 2025, this brings the total dividend for the year to €0.098 per share, which represents a total ordinary dividend of €448 million taking into account the Company's issued share capital, excluding shares held in treasury.</span></p><p class=\"\"><span>Subject to shareholder approval at IAG's Annual General Meeting, the final dividend will be paid from 29 June 2026 to shareholders on the register on 26 June 2026. The dividend will be subject to Spanish withholding tax at the applicable rate (currently 19% or €0.0095 per share), resulting in a net amount per share of €0.0405. </span></p><p class=\"\"><span>IAG also today announces the return of excess cash to shareholders of €1,500 million to be implemented over the course of the next twelve months, starting with a share buyback of €500 million to be completed by the end of May 2026. An announcement will be made in due course with further details.</span></p><p class=\"\"><span>Together, these steps reflect the Board's continued confidence in the Group's strategy, business model and financial position, as well as the long-term prospects for the business.</span></p><p class=\"\"><span>Nicholas Cadbury</span></p><p class=\"\"><span>Chief Financial and Sustainability Officer</span></p><p class=\"\"><span>26 February 2026</span></p><p class=\"\"><span>LEI: 959800TZHQRUSH1ESL13</span></p><p class=\"\"><span>This announcement contains inside information and is disclosed in accordance with the Company's obligations under the Market Abuse Regulation (EU) No 596/2014.</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  DIVUNUWRNSUUUAR</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_RSZ6102Ua:0-reg-intl-con-airline-grp-final-dividend-and-return-of-excess-cash/",
            "pub_date": "2026-02-27 02:27:59",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226013053:0",
            "title": "Pinnacle West Capital Is Maintained at Hold by TD Cowen",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226013053:0/",
            "pub_date": "2026-02-27 02:28:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "stocktwits:3e770c289094b:0",
            "title": "FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><div class=\"summary-diQOvrPB\"><div class=\"summaryTitle-diQOvrPB\">Key points:</div><span><ul class=\"list-bmN0_SHH\"><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>In an interview, Makary defended the FDA's recent, stricter stance on rare disease drug approvals.</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>He specifically mentioned a \"product\" where researchers drilled burr holes in patients' skulls to inject a therapy, which showed no benefit in a randomized trial and had associated morbidity.</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>While Leerink believes Makary was referring to Regenxbio's RGX-121, Stifel thinks he was referring to uniQure AMT-130.</span></li></ul></span></div><span><p class=\"\"><span>Shares of uniQure fell 32% on Thursday on the heels of comments by FDA Commissioner Marty Makary on CNBC on rare disease drug applications.</span></p><p class=\"\"><span>In an interview with CNBC, Makary defended the FDA's recent, stricter stance on rare disease drug approvals. He specifically mentioned a \"product\" where researchers drilled burr holes in patients' skulls to inject a therapy, which showed no benefit in a randomized trial and had associated morbidity.</span></p><p class=\"\"><span>“I have a lot of sympathy for those patients. There's nothing out there to offer them, but we're not going to go ahead and approve something like that that has morbidity associated with it,” he said.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>uniQure’s AMT-130</span></strong></p><p class=\"\"><span>Makary’s comments were deemed a reference to uniQure’s Huntington’s disease gene therapy</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://stocktwits.com/news-articles/markets/equity/uniqure-stock-tumbles-after-fda-meeting/cL2NBqhR3zq\" rel=\"nofollow\" target=\"_blank\"> AMT-130</a><span>, sending shares spiralling.</span></p><p class=\"\"><span>In November, uniQure said that it no longer believes that the FDA considers data from an early-to mid-stage trial of its investigational gene therapy sufficient for approval.</span></p><p class=\"\"><span>The company recently met with the agency, and although the minutes of the meeting have not been received, the company believes that the FDA no longer considers the data from the AMT-130 trial adequate to provide primary evidence in support of an application for approval, it then said.</span></p><p class=\"\"><span>As a result, it is now unclear when the company would apply for approval of the gene therapy, it said. uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Analysts Chip In</span></strong></p><p class=\"\"><span>Leerink, however, noted that the comments seem to point to a drug that had been officially reviewed and rejected, and highlights that Makary also mentioned the drug had morbidity associated with it and there was no cure. The firm believes this is referring to Regenxbio's (RGNX) RGX-121, and not AMT-130.</span></p><p class=\"\"><span>The FDA </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://stocktwits.com/news-articles/markets/equity/why-did-rgnx-shares-plummet-after-hours-today/cZbxnumR4ot\" rel=\"nofollow\" target=\"_blank\">refused </a><span>to approve Regenxbio’s Hunter syndrome gene therapy earlier this month citing insufficient evidence of effectiveness. The company said it is planning to meet with the FDA to address the complete response letter, gather expert input and longer-term clinical data to better define the eligible patient population, and work toward resubmitting its application as quickly as possible.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Stifel Believes Differently</span></strong></p><p class=\"\"><span>Stifel, meanwhile, said that it can see why uniQure's shares are lower on comments from FDA commissioner Makary. Makary was defensive of FDA's approach broadly, as he appeared to maybe refer to the AMT-130 program as an example of something his FDA didn't get behind.</span></p><p class=\"\"><span>To be clear, his specific commentary might/might not have been referring to AMT-130 since uniQure never received an actual complete response letter, the firm noted. While some seem to think Makary was referring to Regenxbio's (RGNX) RGX-121, this doesn't really make sense to Stifel since he describes a drug that didn't beat a control arm, and the Regenxbio study in Hunter was single-arm, it said.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>How Did Stocktwits Users React?</span></strong></p><p class=\"\"><span>On Stocktwits, retail sentiment around QURE stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.</span></p><p class=\"\"><span>Sentiment around RGNX stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.</span></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://stocktwits.com/symbol/QURE\" rel=\"nofollow\" target=\"_blank\">QURE stock</a><span> has risen 45% over the past 12 months, while RGNX gained 25%. </span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/stocktwits:3e770c289094b:0/",
            "pub_date": "2026-02-27 02:28:03",
            "source": "Stocktwits",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938706:0",
            "title": "TRUP: 2026 will see pricing-led growth, margin expansion, and broader customer acquisition strategies",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Revenue growth in 2026 will remain pricing-led, with increased headcount contribution and margin expansion. Customer acquisition is broadening through vets, breeders, and early pet ownership channels, while technology and new products address affordability and efficiency. Investor sentiment is positive, supported by strong free cash flow and disciplined capital allocation.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938706:0-trup-2026-will-see-pricing-led-growth-margin-expansion-and-broader-customer-acquisition-strategies/",
            "pub_date": "2026-02-27 02:29:53",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226013057:0",
            "title": "PROCEPT BioRobotics Is Maintained at Buy by TD Cowen",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226013057:0/",
            "pub_date": "2026-02-27 02:30:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_ACScskdTa:0",
            "title": "CORRECTION FROM SOURCE: ThinkEquity Appoints Adam K. Stern as Head of Private Equity, Merchant & Venture Banking and Forms ThinkStern Ventures",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>This press release corrects a misspelling in the fourth paragraph.</span></p><p class=\"\"><span>NEW YORK, NY / ACCESS Newswire / February 26, 2026 / ThinkEquity, an investment bank and brokerage firm created by experienced professionals that have worked together for over a decade collectively financing more than $100 billion of public and private capital raises, restructurings, and mergers and acquisitions, today announced the addition of Adam K. Stern as Head of Private Equity, Merchant &amp; Venture Banking (MVB) and the formation of ThinkStern Ventures.</span></p><p class=\"\"><span>Adam Stern specializes in providing principal investment capital and strategic advisory services to high-growth private companies across the technology, life sciences, and emerging growth sectors.</span></p><p class=\"\"><span>Adam is recognized for his extensive background in venture capital, private equity, and investment banking, bringing decades of experience and a proven track record of securing funding for disruptive enterprises globally. His leadership will be instrumental in integrating ThinkEquity's strong capital markets capabilities with the dynamic merchant &amp; venture ecosystem. Adam's division and team will be known as ThinkStern Ventures. Adam has joined with his team of professional bankers.</span></p><p class=\"\"><span>Adam's career on Wall Street began in 1987. He has established merchant and venture divisions, including growing existing divisions in many firms such as Josephthal &amp; Company, Spencer Trask Ventures, and SternAegis Ventures/Aegis Capital Corp.</span></p><p class=\"\"><span>Joe Jaigobind, CEO of ThinkEquity, commenting on the firm's strategic growth, said, \"The arrival of an exceptional talent like Adam Stern marks yet another transformative moment for ThinkEquity. The merchant &amp; private market demands integrated expertise and flexible capital that Adam is uniquely qualified to deliver. His deep relationships and unparalleled expertise will significantly enhance our ability to partner with innovative companies throughout their entire growth lifecycle.\"</span></p><p class=\"\"><span>Adam Stern stated, \"I am excited to join ThinkEquity and introduce this ambitious new platform. The mission is to be the premier venture merchant bank for founders and entrepreneurs, providing not just capital, but a hands-on, strategic partnership. We will leverage ThinkEquity's extensive institutional network and distribution to help scale groundbreaking companies and ensure they have the support needed to achieve market leadership.\"</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>About ThinkEquity:</span></strong></p><p class=\"\"><span>ThinkEquity is an investment bank and brokerage firm created by experienced professionals that have worked together for over a decade collectively financing more than $100 billion of public and private capital raises, restructurings, and mergers and acquisitions</span><strong class=\"root-Tkn6WL2y\"><span>.</span></strong><span> ThinkEquity's sector focuses are Healthcare, Technology, Oil &amp; Gas, Metals &amp; Mining, Crypto, Cleantech, Shipping and Consumer. ThinkEquity underwrites IPOs, Secondaries, Uplistings, Dual Listings, Cross Listings &amp; Spacs. ThinkEquity also acts as a placement agent in Registered Directs, Pipes, Private Placements and Debt placements. ThinkEquity performs Merger and Acquisitions, Strategic Advisory Services and Venture Capital placements. Please visit ThinkEquity at www.think-equity.com for more information.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>About ThinkStern Ventures:</span></strong></p><p class=\"\"><span>ThinkStern Ventures is the Venture &amp; Merchant Banking Division of ThinkEquity, specializing in principal investment and strategic advisory services for high-growth private companies.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Contact:</span></strong></p><p class=\"\"><span>Adam Stern</span></p><p class=\"\"><span>Head of Merchant &amp; Venture Banking</span></p><p class=\"\"><span>ThinkEquity</span></p><p class=\"\"><span>646-968-9370</span></p><p class=\"\"><span>adam@think-equity.com</span></p><p class=\"\"><span>William Baquet</span></p><p class=\"\"><span>President</span></p><p class=\"\"><span>ThinkEquity</span></p><p class=\"\"><span>212-732-8500</span></p><p class=\"\"><span>wbaquet@think-equity.com</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>SOURCE:</span></strong><span> ThinkEquity LLC</span></p><p class=\"\"><span>View the original press release on ACCESS Newswire</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_ACScskdTa:0/",
            "pub_date": "2026-02-27 02:30:00",
            "source": "Acceswire",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "modular_finance:72ceaa646556d:0",
            "title": "2cureX AB (publ) publishes Interim Report for the Second Half of 2025",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>2cureX AB (“2cureX” or the “Company”) hereby publishes its interim report for the second half of 2025 (July 1 – December 31, 2025).</span></strong></p><p class=\"\"><span>The second half of 2025 has been characterised by continued execution following the restructuring of the Group and the clarification of 2cureX AB’s commercial role within precision oncology.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>H2 2025 Highlights</span></strong></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Continued operational execution of the restructured Group model</span></li><li class=\"listItem-bmN0_SHH\"><span>Further development of the direct-to-patient access framework</span></li><li class=\"listItem-bmN0_SHH\"><span>Ongoing alignment with hospital-based deployment of IndiTreat®</span></li><li class=\"listItem-bmN0_SHH\"><span>Strategic Letter of Intent (LOI) entered into with PreComb Therapeutics AG</span></li><li class=\"listItem-bmN0_SHH\"><span>First direct-to-patient IndiTreat® test conducted under the “Operation Twin Code” strategy</span></li><li class=\"listItem-bmN0_SHH\"><span>Strengthened governance and certified adviser transition</span></li><li class=\"listItem-bmN0_SHH\"><span>Continued focus on cost control and capital discipline</span></li></ul><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Strategic Developments</span></strong></p><p class=\"\"><span>During H2 2025, 2cureX AB continued to refine its position as a commercial and patient-access focused company. The Company does not conduct product development or regulatory approval activities internally. Instead, it operates alongside strategic partners to support clinically appropriate access to IndiTreat®.</span></p><p class=\"\"><span>The direct-to-patient model has been further defined during the period. The model is designed to support newly diagnosed colorectal cancer patients in understanding and accessing IndiTreat® through collaboration with treating physicians and hospitals. It does not operate outside the healthcare system and remains aligned with clinical practice.</span></p><p class=\"\"><span>2cureX AB also entered into a non-binding Letter of Intent (LOI) with PreComb Therapeutics AG. The LOI outlines a framework for potential collaboration within precision oncology, including treatment guidance, data-driven insights, and potential pharmaceutical engagement. The LOI is subject to the negotiation and execution of definitive agreements.</span></p><p class=\"\"><span>In parallel, the Company continues to operate under its strategic agreement with 2cureX A/S (Denmark), which is responsible for development, regulatory approval including IVDR compliance, and hospital installation of IndiTreat®. Installations are expected to begin in 2026.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Financial Summary (H2 2025)</span></strong></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Net sales: 0 KSEK</span></li><li class=\"listItem-bmN0_SHH\"><span>Other operating income: 3 KSEK</span></li><li class=\"listItem-bmN0_SHH\"><span>Operating result: -644 KSEK</span></li><li class=\"listItem-bmN0_SHH\"><span>Result before tax: -659 KSEK</span></li><li class=\"listItem-bmN0_SHH\"><span>Cash and bank balance at period end: 2,096 KSEK</span></li><li class=\"listItem-bmN0_SHH\"><span>Earnings per share: -0.03 SEK</span></li></ul><p class=\"\"><span>The Company continues to operate with limited revenues and a strong focus on cost control. Expenditures during the period primarily relate to governance, commercial planning, and partner coordination.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Dividend Distribution</span></strong></p><p class=\"\"><span>Dividend distribution remains an important commitment of the Company.</span></p><p class=\"\"><span>As previously communicated:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>The sale of 2cureX A/S generated proceeds of approximately MSEK 5.6</span></li><li class=\"listItem-bmN0_SHH\"><span>In early 2025, MSEK 2.1 was distributed to shareholders</span></li><li class=\"listItem-bmN0_SHH\"><span>The remaining amount is intended to be distributed following the financial review of the Annual Report for 2025</span></li></ul><p class=\"\"><span>The Board remains committed to fulfilling this distribution in a structured and transparent manner.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Outlook</span></strong></p><p class=\"\"><span>Looking ahead, 2cureX AB will continue to:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Refine and execute its commercial access model</span></li><li class=\"listItem-bmN0_SHH\"><span>Support patient engagement aligned with hospital-based deployment of IndiTreat®</span></li><li class=\"listItem-bmN0_SHH\"><span>Maintain strict capital discipline</span></li><li class=\"listItem-bmN0_SHH\"><span>Work closely with strategic partners to ensure coordinated execution</span></li></ul><p class=\"\"><span>While the Company remains in an early commercial phase, the progress made during H2 2025 represents tangible steps toward establishing a sustainable commercial role within precision oncology.</span></p><p class=\"\"><span>The full interim report for H2 2025 is available on the Company’s website.</span></p><p class=\"\"><span>Certified Adviser: Mangold Fondkommission AB</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>For more information about 2cureX:</span></strong></p><p class=\"\"><span>Nathaniel Hutley, Interim CEO</span></p><p class=\"\"><span>E-mail:</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:nh@2curex.com\" rel=\"nofollow\" target=\"_blank\">NH@2curex.com</a></p><p class=\"\"><span>Telephone: +44 (776) 514 1346</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>About 2cureX</span></strong></p><p class=\"\"><span>2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.</span></p><p class=\"\"><span>The first three IndiTreat® tests target patients with metastatic colorectal cancer:</span></p><p class=\"\"><span>•  IndiTreat® Start (first-line therapy)</span></p><p class=\"\"><span>•  IndiTreat® Extend &amp; Explore (third-line options)</span></p><p class=\"\"><span>New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.</span></p><p class=\"\"><span>Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.</span></p><p class=\"\"><span>2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Attachments</span></strong></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://storage.mfn.se/430066a7-f57e-49c2-9f36-6e5a05359305/2curex-quarterly-report-h2-2025.pdf\" rel=\"nofollow\" target=\"_blank\">2curex Quarterly Report H2 2025</a></p></span></div></div>",
            "link": "https://www.tradingview.com/news/modular_finance:72ceaa646556d:0-2curex-ab-publ-publishes-interim-report-for-the-second-half-of-2025/",
            "pub_date": "2026-02-27 02:30:00",
            "source": "MFN by Modular Finance",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_TUC37YRH0:0",
            "title": "IAG Announces Return Of 1,500 Million Euros Excess Cash To Shareholders",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>International Consolidated Airlines Group SA </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>INTL CON AIRLINE GRP  - FINAL DIVIDEND AND RETURN OF EXCESS CASH</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>IAG - RECOMMENDS FINAL DIVIDEND OF €0.05 PER SHARE FOR 2025</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>IAG - ANNOUNCES RETURN OF €1,500 MILLION EXCESS CASH TO SHAREHOLDERS</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>IAG - STARTING WITH SHARE BUYBACK OF €500 MILLION TO BE COMPLETED BY MAY 2026</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUC37YRH0:0-iag-announces-return-of-1-500-million-euros-excess-cash-to-shareholders/",
            "pub_date": "2026-02-27 02:30:11",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM2K4:0",
            "title": "Grifols sees core earnings rising by a quarter as it prioritises profitability",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>    Healthcare company Grifols </span><span> on Thursday said it expects core earnings to grow by more than a quarter in 2026 and will continue to cut debt.</span></p><p class=\"\"><span>Grifols, which makes drugs using blood plasma, has lost about 24% of its market value since January 2024, when Gotham City Research, a short-seller fund, released multiple reports accusing Grifols of overstating earnings and understating debt, which Grifols denies. It has taken legal action against the fund.   </span></p><p class=\"\"><span>The company said it sees its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) growing more than 25% this year to between 1.950 and 1.980 billion euros, and free cash flow of at least 500 million euros  ($588.80 million).</span></p><p class=\"\"><span>\"Our direction for 2026 is clear. We will consciously focus our growth to prioritise profitability, cash flow generation and to continue reducing debt rate,\" said Chief Executive Nacho Abia in a call with analysts, adding that Egypt and Canada would be key markets for the company.  </span></p><p class=\"\"><span>It reported a profit of 402 million euros ($473.96 million) for 2025, more than double what it recorded the previous year, but below analyst expectations in an LSEG poll for net income of 427 million euros. </span></p><p class=\"\"><span>Revenue grew by 7% year on year to 7.5 billion euros, while adjusted EBITDA rose to 1.825 billion euros, it said, both of which matched analyst expectations.</span></p><p class=\"\"><span>Grifols said it exceeded its guidance for free cash flow, totalling 468 million euros excluding any merger and acquisition activities.</span></p><p class=\"\"><span>Net debt fell to 8.8 billion euros in the last quarter of 2025, with a ratio of 5.2 times EBITDA last year compared with 5.6 times in 2024.    </span></p><p class=\"\"><span>($1 = 0.8492 euros)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM2K4:0-grifols-sees-core-earnings-rising-by-a-quarter-as-it-prioritises-profitability/",
            "pub_date": "2026-02-27 02:30:30",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2938657:0",
            "title": "GET: Growth-focused strategy aims for €1B EBITDA by 2030, with rising dividends and high-speed rail expansion",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Management targets €1 billion EBITDA by 2030, driven by growth across all segments, a reset dividend policy, and major investments in high-speed rail, digitalization, and AI. Strong financials, robust cash generation, and a disciplined CapEx approach underpin confidence in sustained value creation.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2938657:0-get-growth-focused-strategy-aims-for-1b-ebitda-by-2030-with-rising-dividends-and-high-speed-rail-expansion/",
            "pub_date": "2026-02-27 02:15:57",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226012984:0",
            "title": "Hormel Says New Tech Makes Advertising More Effective — Market Talk",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Hormel Foods is leveraging technology to drive growth. The company behind brands including Planters, Skippy and Spam says it has incorporated weather-driven demand intelligence into its advertising decisions, specifically for its canned chili brand, Hormel Chili. The move allows the company to better align media spending with consumer buying patterns, President John Ghingo says on a call with analysts. \"And this targeted approach is already delivering stronger returns on investment,\" he adds. (connor.hart@wsj.com)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226012984:0/",
            "pub_date": "2026-02-27 02:16:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226012990:0",
            "title": "Trade Desk Is Maintained at Sector Perform by Scotiabank",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226012990:0/",
            "pub_date": "2026-02-27 02:17:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226012988:0",
            "title": "Salesforce Is Maintained at Outperform by Mizuho",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:17 GMT) </span></strong><span>Salesforce Price Target Cut to $265.00/Share From $280.00 by Mizuho</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226012988:0/",
            "pub_date": "2026-02-27 02:17:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        }
    ]
}